KPV (Capsule)

Description

Oral KPV capsules provide direct gut anti-inflammatory effects through intestinal MC1R activation. KPV (Lys-Pro-Val) is a tripeptide derived from the C-terminal sequence of alpha-melanocyte stimulating hormone (alpha-MSH), which is itself a potent endogenous anti-inflammatory neuropeptide. What makes KPV particularly unique among oral peptides is its ability to directly penetrate intestinal epithelial cells — most peptides cannot cross this barrier, but KPV’s small size and specific sequence allow it to enter cells directly and inhibit NF-kB signaling from within. This intracellular mechanism of action makes oral KPV exceptionally effective for gut inflammation, as it can act on both the luminal surface and within the epithelial cells themselves. Research in animal models of colitis has demonstrated significant reductions in intestinal inflammation, mucosal damage scores, and pro-inflammatory cytokine levels with oral KPV administration. It is particularly relevant for conditions including ulcerative colitis, Crohn’s disease, and general intestinal hyperpermeability.

Key Characteristics

Investigated Benefits

• Direct gut anti-inflammatory action
• IBD and colitis support
• NF-κB inhibition
• Reduced intestinal inflammation
• Systemic anti-inflammatory effects

* Benefits based on preclinical/animal research unless otherwise noted.

Mechanism of Action

“Oral KPV for direct gut anti-inflammatory effects and systemic immune modulation.”

KPV activates melanocortin receptor 1 (MC1R) on intestinal epithelial cells and macrophages, triggering a signaling cascade that prevents NF-kB (nuclear factor kappa B) from translocating to the nucleus. NF-kB is the master regulator of inflammatory gene expression, and its inhibition reduces transcription of pro-inflammatory cytokines including IL-1beta, IL-6, TNF-alpha, and IL-8. Uniquely, KPV can also directly penetrate intestinal epithelial cells through a receptor-independent mechanism, allowing it to inhibit NF-kB signaling intracellularly. This dual mechanism — surface receptor activation and intracellular penetration — makes KPV more effective than compounds that can only act from the luminal surface. KPV also modulates macrophage polarization, shifting intestinal macrophages from a pro-inflammatory M1 phenotype toward an anti-inflammatory M2 phenotype, which promotes mucosal healing and reduces chronic inflammation.

Reconstitution Guide

Research Highlights

1. 1Oral KPV demonstrated anti-inflammatory effects in IBD models
2. 2Direct intestinal epithelium penetration shown
3. 3Reduced colitis severity in animal studies

Compatible Peptides

Peptides commonly used alongside KPV (Capsule) for synergistic effects.